MiNK Therapeutics, Inc.
- INKT
- NASDAQ
- Biotechnology
- Cell Therapy (iNKT)
- Allogeneic Therapeutics
- Cancer Immunotherapy
$9.41
Today −5.33%Quote Oct 16, 2026, 08:00 PM UTC
−19.64%over the last month
Max drawdown −26.1%From 1-month high −26.1%3 months −12.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$48.0M
Quote Oct 16
Next earnings
Nov 12
Expected, not confirmed
Analyst target
$35.00
+271.9% from here
Floor
$9.26
1.6% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about INKTPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
15